FibroGen Inc Cash Flow Conversion Efficiency
FibroGen Inc cash flow conversion efficiency. Based on the latest financial reports, FibroGen Inc (FGEN) has a cash flow conversion efficiency ratio of -0.106x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.85 Million) by net assets ($17.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of FibroGen Inc (2012–2024)
Cash flow conversion efficiency of FibroGen Inc from 2012 to 2024. This chart illustrates how FibroGen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View FibroGen Inc stock quote for real-time trading data and today's change.
FibroGen Inc Cash Flow Conversion Ratio Explained
FibroGen Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
FibroGen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of FibroGen Inc ranked by their cash flow conversion efficiency. Also see FibroGen Inc (FGEN) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shriro Holdings Ltd
AU:SHM
|
0.205x |
|
Samkee Automotive Co. Ltd
KQ:122350
|
0.044x |
|
Janover Inc. Common Stock
NASDAQ:JNVR
|
-0.276x |
|
Kartoon Studios, Inc.
NYSE MKT:TOON
|
0.014x |
|
Hana Must SPAC 2
KQ:208370
|
0.013x |
|
REDCO PRP GROUP LTD -05
F:8KI
|
N/A |
|
Globetronics Tech Bhd
KLSE:7022
|
0.005x |
|
Cellid Co. Ltd
KQ:299660
|
-0.031x |
Annual Cash Flow Conversion Efficiency for FibroGen Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of FibroGen Inc from 2012 to 2024. Review FGEN cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-183.63 Million | $-138.00 Million | 0.751x | -61.31% |
| 2023-12-31 | $-162.20 Million | $-315.02 Million | 1.942x | -98.03% |
| 2022-12-31 | $-1.48 Million | $-145.93 Million | 98.603x | +27572.66% |
| 2021-12-31 | $229.11 Million | $-82.23 Million | -0.359x | -294.16% |
| 2020-12-31 | $441.45 Million | $81.60 Million | 0.185x | +225.75% |
| 2019-12-31 | $535.41 Million | $-78.70 Million | -0.147x | -2.02% |
| 2018-12-31 | $528.47 Million | $-76.14 Million | -0.144x | -26.17% |
| 2017-12-31 | $582.45 Million | $-66.51 Million | -0.114x | -381.33% |
| 2016-12-31 | $175.11 Million | $7.11 Million | 0.041x | +143.02% |
| 2015-12-31 | $196.82 Million | $-18.57 Million | -0.094x | -201.31% |
| 2014-12-31 | $240.68 Million | $22.41 Million | 0.093x | -61.34% |
| 2013-12-31 | $107.60 Million | $25.92 Million | 0.241x | +625.07% |
| 2012-12-31 | $122.18 Million | $-5.61 Million | -0.046x | -- |
About FibroGen Inc
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and o… Read more